Table of Contents
CURRENT MARKET SIZE
ANTI-RHEUMATIC DRUG SALES
ANTI-OSTEOPOROSIS DRUG SALES
ADDRESSABLE PATIENT POPULATION
- RHEUMATOID ARTHRITIS
- OSTEOPOROSIS
CURRENT TREATMENTS
- RHEUMATOID ARTHRITIS TREATMENTS
- OSTEOPOROSIS TREATMENTS
- RHEUMATOID ARTHRITIS SALES DRIVERS
- OSTEOPOROSIS SALES DRIVERS
- RHEUMATOID ARTHRITIS SALES BREAKERS
- OSTEOPOROSIS SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUGS LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010
- Actemra (Roche/Chugai)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Bazedoxifene (Wyeth)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Cimzia (UCB/Celltech)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- CNTO 148 (Johnson & Johnson/Schering-Plough)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Denosumab (Amgen)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Entereg (GlaxoSmithKline/Adolor)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Febuxostat (TAP Pharmaceutical Products)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Orencia (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Preos (NPS Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - COMPANIES
| 
View Cart
